Csl Limited

Other

The University of Queensland

Iscotec A.b.

John Cooper Cox

Ian Hector Frazer

Elizabeth Ann Webb

Stirling John Edwards

Andreas Suhrbier

Margaret Bridget Holland Moloney

Nigel Alan John McMillan

Mark Philip Williams

Debbie Pauline Drane

Mary Brigid Margetts

Bror Morein

Irwin C Jacobs

Robert E Sparks

Norbert S Mason

Karin Lovgren-Bengtsson

Alan Robert Coulter

Sigrid Elisabet Sjolander

Bo Sundquist

Bengt John Lennart Ronnberg

A method of preparing anti-b amyloid immunoglobulin involves treating human plasma anti-b amyloid immunoglobulin under alkaline conditions, such as at pH 10.25 to 11.75 using diethylamine HCl, to dissociate b amyloid protein therefrom. Typically, the anti-b amyloid immunoglobulin is present in human immunoglobulin preparations obtained from plasma or serum. Anti-b amyloid immunoglobulin prepared by the method is substantially free of b amyloid protein and has therapeutic activity in compositions and/or methods for treating a disease or condition associated with b amyloid plaques, such as Alzheimer's disease.

Therapeutic antibody purification method and method of use

The present invention relates generally to an immunogenic complex comprising a charged organic carrier and a charged antigen and, more particularly, a negatively charged organic carrier and a positively charged antigen. The complexes of the present invention are useful, inter alia, as therapeutic and/or prophylactic agents for facilitating the induction of a cytotoxic T-lymphocyte response to an antigen.

Immunogenic complexes and methods relating thereto

An immunostimulating complex comprising one or more ganglosides, illustrated by the ganglosides GM2, GD2, GD3 or GT3, is useful as a prophylactic or therapeutic agent in the treatment of tumors, inter alia, especially melanomas.

Ganglioside immunostimulating complexes and uses thereof

A papillomavirus polyprotein construct comprises at least two amino acid sequences fused directly or indirectly together, each of the sequences being the sequence of an early ORF protein of papillomavirus or an immunogenic variant or fragment thereof, and at least one of said sequences being other than the E6 or E7 protein sequence or an immunogenic variant or fragment thereof. Nucleic acid molecules encoding the polyprotein construct, prophylactic or therapeutic compositions comprising the polyprotein construct or the nucleic acid molecule, and methods for eliciting an immune response against papillomavirus in a host animal are also provided.

Papillomavirus polyprotein constructs

Peptides, antibodies and recombinant expression systems or cells that contain and express a DNA insert of HPV encoding a region of a papilloma induced or a papilloma protein, such as E6 or E7, are produced. Compositions containing these peptides, antibodies and/or recombinant cells are utilized as immunogenic compositions and in methods for inhibiting and treating HPV infection and tumor initiation and progression. Specific peptides and recombinant cells, such as vaccinia virus and tumor cells, that express epitopic regions of the HPV16 E6 or E7 nucleoprotein are particularly described.

Saponin preparations based on defined compositions of purified saponin fractions derived from the bark of Molina are disclosed. The saponin preparations are useful in immunostimulating complex (iscom) matrices. The saponin preparations, and iscom matrices prepared using them, have particular activity as adjuvants.

Saponin preparations and use thereof in iscoms

Variants of human papilloma virus (HPV) E6 and E7 proteins able to elicit a humoral and/or cellular immune response against HPV in a host animal but not being cell-transforming in the host animal are disclosed, and are useful in treatment or prevention of diseases or conditions involving HPV.

Variants of human papilloma virus antigens

Variants of human papillomavirus antigens

Spray dried vaccine preparation comprising aluminium adsorbed immunogens

Growing community of inventors

Bullengarook, Australia

John Cooper Cox